Novocure Ltd - Asset Resilience Ratio
Novocure Ltd (NVCR) has an Asset Resilience Ratio of 43.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Novocure Ltd (NVCR) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Novocure Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Novocure Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Novocure Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Novocure Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $344.48 Million | 43.72% |
| Total Liquid Assets | $344.48 Million | 43.72% |
Asset Resilience Insights
- Very High Liquidity: Novocure Ltd maintains exceptional liquid asset reserves at 43.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novocure Ltd Industry Peers by Asset Resilience Ratio
Compare Novocure Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Novocure Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Novocure Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.03% | $354.13 Million | $804.33 Million | -20.13pp |
| 2024-12-31 | 64.16% | $796.11 Million | $1.24 Billion | +5.72pp |
| 2023-12-31 | 58.44% | $669.79 Million | $1.15 Billion | -13.23pp |
| 2022-12-31 | 71.67% | $854.10 Million | $1.19 Billion | +7.71pp |
| 2021-12-31 | 63.97% | $728.90 Million | $1.14 Billion | +6.18pp |
| 2020-12-31 | 57.79% | $607.90 Million | $1.05 Billion | +26.76pp |
| 2019-12-31 | 31.03% | $148.77 Million | $479.45 Million | +0.05pp |
| 2018-12-31 | 30.98% | $105.26 Million | $339.79 Million | -8.50pp |
| 2017-12-31 | 39.47% | $104.72 Million | $265.30 Million | -3.02pp |
| 2016-12-31 | 42.49% | $119.85 Million | $282.08 Million | -6.32pp |
| 2015-12-31 | 48.81% | $150.00 Million | $307.34 Million | +10.63pp |
| 2014-12-31 | 38.17% | $45.00 Million | $117.88 Million | +37.55pp |
| 2013-12-31 | 0.62% | $1.18 Million | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more